HypoBio: The company’s HPV21 typing detection reagent has won the National Invention Patent Gold Award and has been widely used in clinical HPV detection.

Some investors asked on the investor interactive platform: How many hpv tests have the company completed in 2021? How many cases of two cancers have been tested?

　　Cap Bio(300639.SZ) stated on the investor interactive platform on March 17 that the company is a pioneer and promoter of promoting the use of molecular diagnostics to detect cervical cancer in China, and has constructed an integrated business model of “nucleic acid testing products + medical testing services”. It occupies a leading position in the field of HPV nucleic acid detection in China. At present, it has developed a series of HPV detection products for cervical cancer, which can be purchased and used by medical institutions, and provide HPV detection services through third-party medical laboratories. The cervical cancer HPV detection series products developed by the company can meet the different needs of clinical, screening and scientific research. The company’s HPV21 typing detection reagent has won the National Invention Patent Gold Award and has been widely used in clinical HPV detection. The PCR platform was developed to better meet the needs of the two cancer screening projects for rural women, and has been widely used in the two cancer screening; HPV37 typing test is currently the most typed detection product on the market. Clinical trial work on products such as cervical cancer methylation. After years of clinical application, the company’s product quality and technical services have been highly recognized by customers. As a strategic partner of China’s cervical cancer prevention and control project, the company will continue to devote itself to the promotion of cervical cancer HPV detection, strive to maximize the market expansion of HPV products, and further increase market share.

(Article source: Daily Economic News)

Article source: Daily Economic News

Responsible editor: 65

Original title: Kaipu Bio: The company’s HPV21 typing detection reagent has won the National Invention Patent Gold Award and has been widely used in clinical HPV detection